Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.37 |
| ▸ | NAMPT | P43490 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL479835 | 0.95 | PDCD1 (0.38) | PDCD1CD274HDAC1HIF1ANAMPT | |
| SCHEMBL480833 | 0.93 | MAPT (0.44) | PDCD1CD274HDAC1NAMPTMAPT | |
| SCHEMBL2574498 | 0.93 | HDAC1 (0.45) | HDAC1HIF1ANAMPTMAPTCA1 | |
| SCHEMBL3844906 | 0.90 | KMT2A (0.39) | CD274HDAC1NAMPTDDB1CRBN | |
| SCHEMBL2572833 | 0.90 | HIF1A (0.38) | HIF1ANAMPTLMNAHPGDMAPT | |
| SCHEMBL4487854 | 0.90 | PDCD1 (0.43) | PDCD1CD274HDAC1NAMPTDDB1 | |
| SCHEMBL479562 | 0.90 | HIF1A (0.40) | PDCD1CD274HIF1ANAMPTLMNA | |
| SCHEMBL479564 | 0.90 | HIF1A (0.40) | PDCD1CD274HIF1ANAMPTLMNA | |
| SCHEMBL3156622 | 0.89 | HDAC1 (0.37) | PDCD1CD274HDAC1HIF1ANAMPT | |
| SCHEMBL479462 | 0.89 | MAPT (0.43) | PDCD1CD274HDAC1NAMPTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20200330435-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2020-10-22 | — | — | US | disclosed |
| EP-3643309-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2020-04-29 | — | — | EP | disclosed |
| US-20190038600-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DEISEASES | BOEHRINGER INGELHEIM INT (DE) | 2019-02-07 | — | — | US | disclosed |
| US-10154990-B2 | Medicaments for the treatment or prevention of fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-12-18 | — | — | US | disclosed |
| US-9844572-B2 | Promotion of neuronal integration in neural stem cell grafts | LIFE & BRAIN GMBH (DE) | 2017-12-19 | — | — | US | disclosed |
| EP-2411034-B1 | PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS | LIFE & BRAIN GMBH (DE) | 2017-07-26 | — | — | EP | disclosed |
| US-20160136133-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-05-19 | — | — | US | disclosed |
| EP-2878297-A1 | Medicaments for the treatment or prevention of fibrotic diseases | Boehringer Ingelheim International GmbH (DE) | 2015-06-03 | — | — | EP | disclosed |
| US-20140296217-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-02 | — | — | US | disclosed |
| US-20120093832-A1 | PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS | LIFE & BRAIN GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| EP-2411034-A1 | PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS | Life & Brain GmbH (DE) | 2012-02-01 | — | — | EP | disclosed |
| EP-2384751-A1 | Medicaments for the treatment or prevention of fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-09 | — | — | EP | disclosed |
| WO-2010108665-A1 | PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS | LIFE & BRAIN GMBH (DE) | 2010-09-30 | — | — | WO | disclosed |
| US-20100204211-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | disclosed |
| EP-2157081-A1 | Indolinones substituted in six locations, their manufacture and their application as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2010-02-24 | — | — | EP | disclosed |
| US-20060142373-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
| US-6762180-B1 | Substituted indolines which inhibit receptor tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204211-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | PDCD1 4138/4885CD274 4350/4885HDAC1 430/4885 |
| US-20060142373-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | MMP1, COL1A1, FOXM1 | PDCD1 4138/4885CD274 4350/4885HDAC1 430/4885 |
| US-20200330435-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | PDCD1 4138/4885CD274 4350/4885HDAC1 430/4885 |
| US-20160136133-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | PDCD1 4138/4885CD274 4350/4885HDAC1 430/4885 |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, SMAD3 | PDCD1 4385/4885CD274 4560/4885HDAC1 448/4885 |
| US-10154990-B2 | Medicaments for the treatment or prevention of fibrotic diseases | MMP1, COL1A1, FOXM1 | PDCD1 4138/4885CD274 4350/4885HDAC1 430/4885 |
| US-20120093832-A1 | PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS | DCX, NGF, BDNF | PDCD1 4077/4885CD274 3560/4885HDAC1 2264/4885 |
| US-20140296217-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | PDCD1 4138/4885CD274 4350/4885HDAC1 430/4885 |
| US-20190038600-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DEISEASES | MMP1, COL1A1, IDO1 | PDCD1 1924/4885CD274 2828/4885HDAC1 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.